导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.03% | 1454/4773 |
| 近一周 | -2.50% | 2378/5462 |
| 近一月 | -4.82% | 2789/5421 |
| 近一季 | -8.82% | 2975/5209 |
| 近半年 | -6.18% | 3032/4920 |
| 近一年 | 7.89% | 1249/4366 |
| 近两年 | 68.95% | 993/2954 |
| 近三年 | 37.15% | 794/2253 |
| 成立以来 | 44.53% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.93% 1130/4961 |
18.91% 1336/5312 |
- - |
- - |
| 2025 | 29.93% 1360/4813 |
2.10% 1465/3635 |
1.65% 2242/4076 |
23.96% 1500/4524 |
0.99% 1619/4813 |
| 2024 | 6.88% 1715/3463 |
-2.26% 1341/2808 |
-5.04% 1626/3014 |
15.28% 1763/3129 |
-0.11% 1321/3463 |
| 2023 | -3.85% 652/2656 |
7.80% 523/2280 |
-3.66% 857/2385 |
-3.59% 956/2515 |
-3.97% 833/2655 |
| 2022 | -16.75% 509/2207 |
-13.32% 734/1919 |
3.54% 1136/2016 |
-9.93% 327/2113 |
2.99% 791/2208 |
| 2021 | - - |
- - |
11.16% 391/1330 |
6.22% 237/1466 |
4.12% 366/1822 |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 东财中证500C VS. 长安沪深300非周期A(740101) |